Form 8-K Esperion Therapeutics, For: Oct 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Form 8-K Esperion Therapeutics, For: Oct 18
October 19, 2021 6:26 AM EDT
Cowen analyst Joseph Thome lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $30.00 (from $60.00) while maintaining an Outperform rating.
The analyst commented, "ESPR announced organizational changes to conserve cash in a challenging launch environment ahead of the Q1:23 CV Outcomes... More
October 18, 2021 6:08 PM EDT
Credit Suisse analyst Judah Frommer downgraded Esperion Therapeutics (NASDAQ: ESPR) from to Neutral with a price target of $11.00 (from $28.00).
The analyst comments "Following a challenged launch for bempedoic acid during the Covid-19 pandemic, along with administrative complications borne out of preauthorization requirements for many prescriptions, Esperion communicated a shift in strategy to... More
